EU MDR Article 10a: Supply Chain Discontinuation Reporting and Shortage Prevention for Medical Devices

What Is Article 10a and Why It Matters

Article 10a of Regulation (EU) 2017/745 (MDR) -- and the corresponding Article 10a of Regulation (EU) 2017/746 (IVDR) -- establishes a mandatory pre-emptive notification requirement for manufacturers who anticipate an interruption or discontinuation in the supply of a medical device or IVD that could result in serious harm or risk of serious harm to patients or public health in one or more EU Member States.

The provision was introduced by Regulation (EU) 2024/1860, which amended both the MDR and IVDR. It has applied since January 10, 2025.

This is a separate and distinct reporting obligation from existing vigilance requirements (MDR Articles 87-89), periodic safety update reports (PSURs), and general post-market surveillance duties. It does not replace any of those mechanisms. Article 10a sits alongside them as a forward-looking supply chain safeguard.

The policy rationale is straightforward: EU institutions observed that device shortages often materialize before competent authorities and healthcare providers have time to arrange alternatives. Article 10a forces early disclosure so that mitigation actions -- procurement of substitute devices, regulatory fast-tracking of alternatives, temporary authorizations under MDR Article 59 -- can begin before supply gaps translate into patient harm.

Legal Basis and Key Documents

Document	Description	Date
Regulation (EU) 2024/1860	Amending regulation that introduced Article 10a into MDR and IVDR	Entered into force late 2024
MDCG 2024-16	Notification form template for Article 10a reports	Published 2024
MDCG 2024-16 Annex	Device identification table accompanying the notification form	Published 2024
European Commission Q&A	Questions and answers on Article 10a implementation	October 2024 (Rev. 0), updated December 2024 (Rev. 1) and April 2026 (Rev. 2)
MedTech Europe / AESGP / COCIR Decision Guide	Joint industry flowchart for determining whether Article 10a applies	March 2025

Manufacturers should treat the MDCG 2024-16 form as the definitive template. Competent authorities expect notifications submitted in this format. The European Commission Q&A document provides interpretive guidance on the most common implementation questions and has been updated as of April 2026 to reflect early experience with the regulation.

Scope: Who Must Report

The Manufacturer Bears Sole Responsibility

The legal obligation to notify rests exclusively on the manufacturer, regardless of whether the manufacturer is established inside or outside the European Union.

Key points:

• Cannot delegate legal responsibility. The manufacturer remains legally accountable for the notification decision and its content, even if an authorized representative or third-party consultant prepares and submits the form.
• Can engage authorized representatives or consultants for practical implementation. There is no prohibition on using an EC Rep, regulatory consultant, or other third party to gather the required information, draft the notification, and manage the submission process -- provided the manufacturer retains decision-making authority and approves the content.
• Custom-made devices are excluded. The only explicit exemption from Article 10a is custom-made devices as defined in MDR Article 2(3).

Legacy Devices Are In Scope

Article 10a applies not only to devices fully certified under MDR/IVDR, but also to legacy devices benefiting from the transitional provisions:

• MDR Article 120(3a) and (3b) legacy devices
• IVDR Article 110(3a) and (3b) legacy devices

This is significant because many legacy devices remain on the EU market under extended transition timelines. If a manufacturer decides not to pursue MDR/IVDR certification for a legacy device -- or loses the certificate or conformity assessment agreement required to maintain transition eligibility -- that decision can trigger an Article 10a notification if serious harm is foreseeable.

Recommended Reading

GB PMSR/PSUR Dual-Report Architecture: How to Structure Post-Market Surveillance Reports for Devices Sold in Both EU and Great Britain

Post-Market Surveillance EU MDR / IVDR2026-05-05 · 18 min read

When the Reporting Obligation Is Triggered

The notification obligation is triggered when both of the following conditions are met:

1. The manufacturer anticipates an interruption or discontinuation of supply of a device
2. It is reasonably foreseeable that this interruption or discontinuation could result in serious harm or risk of serious harm to patients or public health in one or more Member States

Defining Interruption vs. Discontinuation

Concept	Definition	Practical Threshold
Interruption	Temporary inability to place the device on the market or make it available	Expected duration of more than 60 days is used as a general indication. Interruptions shorter than 60 days may still be reportable if the risk profile warrants it.
Discontinuation	Permanent cessation of placing the device on the market	Any permanent cessation of a device that meets the serious harm threshold.

The 60-day threshold for interruptions is a general indicator, not an absolute safe harbor. If a device is used in acute, life-threatening situations where even a 30-day gap could cause serious harm, the manufacturer should not wait until day 61 to notify.

The Six-Month Advance Notice Rule

Manufacturers must submit the notification at least 6 months before the anticipated date of interruption or discontinuation, unless exceptional circumstances make this impossible.

"Exceptional circumstances" is not defined in the regulation itself, but the Commission Q&A gives examples such as natural disasters, sudden loss of a critical supplier, or other force majeure events. Even in exceptional circumstances, the manufacturer must notify as soon as reasonably practicable.

Categories of Reportable Reasons

The European Commission Q&A and MDCG guidance identify four broad categories of reasons that may trigger Article 10a:

Regulatory Reasons

• Loss of compliance with transition conditions under MDR Article 120 or IVDR Article 110
• Delay in obtaining MDR/IVDR certification before a transition deadline expires
• Suspension or withdrawal of a conformity assessment certificate by a Notified Body
• Manufacturer's deliberate decision not to pursue MDR/IVDR certification for a legacy device
• Failure to meet the QMS, NB application, or NB agreement deadlines required for transition eligibility

Regulatory reasons are expected to be the most common trigger during the MDR/IVDR transition period, particularly as the 2027-2029 deadlines approach for different device classes.

Manufacturing Reasons

• Device performance issues that lead the manufacturer to halt production
• Persistent quality failures requiring extended manufacturing shutdowns
• Inability to maintain validated manufacturing processes

Supply Chain Reasons

• Shortage of critical raw materials or components
• Loss of a sole-source supplier
• Geopolitical disruptions to supply routes
• Export restrictions on key materials

Other Reasons

• Commercial or business decisions to withdraw a device from the market
• Strategic portfolio rationalization
• Events such as natural disasters, fires, or floods affecting production facilities

A commercial decision to discontinue a device is not exempt from Article 10a. If the device is used in life-sustaining or life-supporting applications and no equivalent alternative exists, the manufacturer must notify regardless of the commercial rationale.

The Serious Harm Assessment

Definition and Alignment with MDCG 2023-3

The concept of "serious harm" in Article 10a is aligned with the definition established in MDCG 2023-3 (the guidance on vigilance terms and definitions). In practical terms, it covers harm that:

• Is life-threatening
• Results in permanent impairment of a body function or permanent damage to a body structure
• Necessitates medical or surgical intervention to prevent permanent impairment or damage
• Results in hospitalization or prolongation of existing hospitalization

The Alternatives Test

A critical element of the serious harm assessment is evaluating whether equivalent alternative devices are available from other manufacturers.

The manufacturer must:

1. Identify whether alternative devices exist on the EU market that serve the same clinical purpose
2. Assess whether those alternatives are available in sufficient quantity to meet demand across affected Member States
3. Consider whether switching to an alternative is clinically feasible within the relevant time frame (some alternatives require clinician retraining or institutional changeover periods)

If an equivalent alternative exists and is readily available, the manufacturer may conclude that serious harm is not reasonably foreseeable, and notification may not be required. However, the assessment must be realistic and comprehensible -- the Commission Q&A explicitly warns against superficial analyses that merely assert alternatives exist without substantiating the claim.

Documenting the Assessment

Even when a manufacturer concludes that notification is not required (because alternatives exist), the assessment itself should be documented internally. Competent authorities may request evidence of the manufacturer's reasoning during inspections or audits.

Recommended Reading

CMS Proposes Repealing NTAP Alternative Pathway for Breakthrough Devices: What the FY 2027 IPPS Rule Means for MedTech Commercialization

Reimbursement & Market Access Regulatory2026-05-20 · 20 min read

The Decision Flowchart

The following decision logic summarizes the Article 10a applicability assessment. This is based on the joint flowchart published by MedTech Europe, AESGP, and COCIR in March 2025.

Step-by-Step Decision Logic

Step 1: Is the device in scope?

• Is it a medical device or IVD placed on the EU market (including legacy devices under transition)?
• Is it a custom-made device? If yes -- excluded from Article 10a.
• If no to the first question -- Article 10a does not apply.

Step 2: Does the manufacturer anticipate an interruption or discontinuation?

• Is there a foreseeable event that will prevent the manufacturer from placing the device on the EU market?
• If no foreseeable interruption or discontinuation -- no notification required at this time (but must monitor continuously).
• If yes -- proceed to Step 3.

Step 3: Is the interruption/discontinuation expected to last more than 60 days or be permanent?

• If the interruption is temporary and expected to last 60 days or less, consider whether the risk profile of the device still warrants notification despite the short duration.
• If the interruption exceeds 60 days or is permanent -- proceed to Step 4.

Step 4: Is serious harm reasonably foreseeable?

• Apply the serious harm definition from MDCG 2023-3.
• Consider the clinical context: is the device used in life-threatening, life-sustaining, or critical care situations?
• Proceed to Step 5.

Step 5: Do equivalent alternatives exist?

• Are there other devices on the EU market that can serve the same clinical purpose?
• Are they available in sufficient quantity?
• Is clinical switching feasible within the relevant timeframe?
• If alternatives exist and are sufficient -- notification may not be required, but document the rationale.
• If no sufficient alternatives -- notification is required. Proceed to Step 6.

Step 6: Submit the notification.

• Complete MDCG 2024-16 form and Annex.
• Submit at least 6 months before the anticipated date (unless exceptional circumstances).
• Notify the competent authority and direct supply chain partners.

Flowchart Summary Table

Decision Point	Yes Path	No Path
Device in scope (MDR/IVDR, not custom-made)?	Continue	Article 10a does not apply
Anticipated interruption or discontinuation?	Continue	No notification now; continue monitoring
Duration > 60 days or permanent?	Continue	Consider risk profile; may still notify
Serious harm reasonably foreseeable?	Continue	No notification required
Equivalent alternatives available and sufficient?	Document rationale; notification may not be required	Notification required

What the Notification Must Contain

The MDCG 2024-16 form specifies the required content. At a minimum, the notification must include:

Device Identification

• Device name and trade name
• Basic UDI-DI
• Device model/catalog number
• Risk classification (MDR class or IVDR class)
• Whether the device is a legacy device under transition provisions

Manufacturer Information

• Manufacturer name and address
• Authorized representative name and address (if manufacturer is outside the EU)
• Single Registration Number (SRN) in EUDAMED

Reason for Interruption/Discontinuation

• Category of reason (regulatory, manufacturing, supply chain, other)
• Detailed description of the circumstances
• Whether the interruption is temporary or permanent
• Expected start date and expected duration

Market Impact Assessment

• Member States affected
• Estimated volume of devices affected
• Serious harm assessment and rationale
• Assessment of equivalent alternatives (or justification for why none exist)

Proposed Mitigation Measures

• Any actions the manufacturer is taking to minimize the impact
• Proposed timeline for resolution (if temporary interruption)
• Suggested alternative devices, if known

The MDCG 2024-16 Annex (Device Identification table) should be completed for each device or device family covered by the notification.

Who Receives the Notification

Article 10a establishes a two-channel notification requirement:

Channel 1: Competent Authority

The manufacturer must notify the competent authority of the Member State where the manufacturer (or its authorized representative) is established.

Once a competent authority receives a notification, it must:

• Inform other Member State competent authorities without undue delay
• Inform the European Commission without undue delay

This cross-border information sharing ensures that all affected Member States are aware of the potential shortage, even if the manufacturer's establishment is in a different country from where the patients are at risk.

Channel 2: Direct Supply Chain Partners

The manufacturer must also notify the following parties to whom it directly supplies the device:

• Importers
• Distributors
• Procedure pack producers
• Health institutions (hospitals, clinics, etc.)
• Healthcare professionals

This is a critical design feature of Article 10a: the notification obligation extends beyond regulators into the supply chain itself, ensuring that the entities closest to patient care are informed early.

Recommended Reading

Global UDI Compliance 2026: Complete Deadlines Guide by Country (EU, US, Switzerland, Australia, China, Brazil, Singapore)

Labeling & UDI EUDAMED2026-05-04 · 14 min read

The Cascading Notification Requirement

Article 10a imposes a downstream cascade obligation. Economic operators who receive a manufacturer's Article 10a notification must forward it without undue delay to:

• Other economic operators further down the supply chain
• Health institutions
• Healthcare professionals

to whom they in turn supply the device.

Rules for Cascading

The regulation is specific about how the cascade must operate:

1. No modification permitted. Economic operators must forward the manufacturer's communication without changing, adding to, or paraphrasing the content. The notification must reach downstream recipients in the manufacturer's original form.
2. "Without undue delay." There is no fixed deadline expressed in days, but the expectation is transmission within a short, defensible period after receipt.
3. Applies to all economic operators in the chain. Importers, distributors, and procedure pack producers all bear this obligation. Each must pass the notification to its own downstream customers.

Practical Implications

The cascading requirement means that a manufacturer's notification wording matters enormously. Because downstream operators cannot modify the content, the manufacturer must ensure the communication is clear, complete, and appropriate for all audiences in the supply chain -- from procurement managers at distributors to clinical staff at hospitals.

Manufacturers should draft the notification with both regulatory and clinical audiences in mind. Technical jargon should be accompanied by plain-language summaries. Contact information for questions should be prominent.

Relationship to Other Reporting Obligations

Article 10a does not replace or modify any existing reporting requirements. Manufacturers must continue to comply with:

Obligation	Legal Basis	How It Differs from Article 10a
Serious incident reporting	MDR Article 87(1), IVDR Article 82(1)	Reports on incidents that have already occurred. Article 10a is prospective.
Field safety corrective action (FSCA)	MDR Article 87(2), IVDR Article 82(2)	Addresses risks from specific device defects. Article 10a addresses supply disruption risks.
Periodic Safety Update Report (PSUR)	MDR Article 86, IVDR Article 81	Summarizes post-market data at intervals. Article 10a is event-driven.
Trend reporting	MDR Article 88, IVDR Article 83	Reports on statistically significant increases in non-serious incidents.
PSMP / PMS plan updates	MDR Article 84, IVDR Article 79	Ongoing surveillance plans. Article 10a is a specific notification triggered by supply events.

A single event may trigger multiple reporting obligations simultaneously. For example, a manufacturing defect that causes both a device recall (FSCA) and a supply interruption (Article 10a) requires separate notifications under each framework.

Practical Implementation Steps

1. Establish a Supply Chain Risk Register

Create and maintain a register of all devices placed on the EU market that catalogs:

• Device name, classification, and UDI-DI
• Whether the device is used in life-threatening or life-sustaining applications
• Known alternative devices and their manufacturers
• Sole-source raw materials or components
• Current supply chain lead times
• Regulatory status (full MDR/IVDR certification vs. legacy device under transition)

This register forms the foundation of the Article 10a monitoring process. Without it, manufacturers cannot systematically assess whether an interruption meets the serious harm threshold.

2. Implement Continuous Monitoring

Article 10a requires manufacturers to monitor for potential supply disruptions proactively. This is not a periodic review exercise -- it is a continuous obligation. Practical steps include:

• Quarterly reviews of supply chain risk indicators for all EU-market devices
• Integration of Article 10a triggers into the change control process (e.g., decisions to discontinue a product line must include an Article 10a assessment)
• Monitoring of Notified Body certification status and any signals of potential certificate suspension or withdrawal
• Tracking of MDR/IVDR transition deadlines and the manufacturer's progress toward certification

3. Pre-Populate Notification Templates

For devices identified as high-risk (no alternatives, used in critical care), pre-populate the MDCG 2024-16 form and Annex with device identification and manufacturer information. This reduces the time required to submit a notification when a trigger event occurs, which is particularly important given the 6-month advance notice requirement.

4. Train Commercial and Supply Chain Teams

The personnel most likely to learn about a potential supply interruption first are often in sales, supply chain management, or operations -- not regulatory affairs. These teams need training to:

• Recognize events that may trigger Article 10a
• Escalate potential triggers to the regulatory affairs function promptly
• Understand that commercial confidentiality does not override the Article 10a obligation

5. Define Internal Escalation Procedures

Establish a clear internal workflow that specifies:

• Who is responsible for making the Article 10a notification decision
• Who prepares the notification content
• Who approves the notification before submission
• How the notification is distributed to direct supply chain partners
• How confirmation of cascading by economic operators is tracked

6. Coordinate with Authorized Representatives

For manufacturers outside the EU, the authorized representative plays a critical practical role. While the manufacturer retains legal responsibility, the authorized representative often has established communication channels with the relevant competent authority and can facilitate submission of the MDCG 2024-16 form.

Recommended Reading

FDA Commissioner Makary Resigns: Leadership Crisis, Workforce Collapse, and What It Means for Medical Device Regulation in 2026

Regulatory Quality Systems2026-05-20 · 21 min read

Industry Concerns and the 2026 Landscape

MedTech Europe's Assessment

In a May 2026 article, MedTech Europe described Article 10a as "a new bureaucratic challenge for manufacturers" and raised several concerns:

• Lack of advance stakeholder consultation. The requirement was introduced with limited opportunity for industry input on practical implementation details.
• Continuous monitoring burden. Companies must continuously monitor their entire product portfolio for potential supply disruptions, which requires dedicated resources and processes.
• Competitor monitoring. The alternatives assessment requires manufacturers to monitor whether competitors can supply equivalent devices -- information that is not always readily available and raises questions about competitive intelligence boundaries.
• Standardized notification form. The Commission is empowered to adopt delegated acts specifying the notification form and procedures, which introduces additional regulatory uncertainty.

December 2025 EU Simplification Proposal

The EU's December 2025 simplification proposal includes amendments to Article 10a that would:

• Introduce enhanced coordination mechanisms between Member States for managing supply interruptions
• Grant the Commission power to adopt delegated acts on notification procedures, potentially standardizing submission formats and timelines further
• Create additional mechanisms for managing supply interruptions at the EU level, beyond the current manufacturer-to-CA-to-CA information chain

As of May 2026, these simplification proposals are still working through the legislative process. Manufacturers should monitor developments but continue to comply with the current Article 10a requirements as enacted by Regulation (EU) 2024/1860.

Common Questions and Pitfalls

"We are discontinuing a device for commercial reasons. Does Article 10a apply?"

Yes, if the device meets the serious harm threshold and no sufficient alternatives exist. The reason for discontinuation is irrelevant to the notification obligation. A purely commercial decision to discontinue a life-sustaining device triggers Article 10a just as much as a manufacturing failure.

"Our device has several competitors offering similar products. Do we still need to notify?"

Conduct the alternatives assessment carefully. If multiple equivalent devices are available in sufficient quantity, and clinical switching is feasible, notification may not be required. Document the assessment. However, if your device is a preferred choice in specific clinical protocols, or if the alternatives have different performance characteristics, the assessment may support notification.

"Can we notify just our authorized representative and let them handle the rest?"

No. The manufacturer must notify both the competent authority and its direct supply chain partners. The authorized representative can assist with the competent authority notification, but the manufacturer must separately communicate with its importers, distributors, and direct healthcare customers.

"What if we are unsure whether the 6-month deadline applies?"

Submit the notification as early as possible. There is no penalty for early notification, but late notification can result in regulatory action by competent authorities. If you are uncertain, err on the side of notifying.

"Does Article 10a apply to devices we export to the EU but do not 'place on the market' ourselves?"

If your company is the manufacturer as defined in MDR Article 2(1) -- i.e., you make or redesign a device and it is placed on the EU market under your name or trademark -- Article 10a applies to you regardless of whether you directly handle EU distribution. The obligation follows the manufacturer designation.

Summary of Key Obligations

Element	Requirement
Who notifies	The manufacturer (sole legal responsibility)
What triggers notification	Anticipated interruption (> 60 days) or discontinuation + foreseeable serious harm
When to notify	At least 6 months in advance (except exceptional circumstances)
Where to notify	Competent authority of establishment Member State + direct supply chain partners
What form to use	MDCG 2024-16 and Annex
Cascading	Economic operators must forward manufacturer's notification without modification and without undue delay
Scope	All MDR/IVDR devices and legacy devices, excluding custom-made devices
Relationship to other obligations	Separate from and in addition to vigilance, PSUR, FSCA, and PMS reporting

Article 10a represents a fundamental shift in the EU regulatory landscape: it requires manufacturers to think proactively about the supply chain consequences of their business and regulatory decisions, and to disclose those consequences to regulators and healthcare providers before patients are harmed. For regulatory affairs and quality assurance professionals, integrating Article 10a compliance into existing change control, supply chain management, and post-market surveillance systems is not optional -- it is a legal requirement that has been enforceable since January 10, 2025.